Format

Send to

Choose Destination
Eur J Paediatr Neurol. 2014 Jan;18(1):19-24. doi: 10.1016/j.ejpn.2013.07.003. Epub 2013 Sep 10.

Continuation rates of levetiracetam in children from the EULEVp cohort study.

Author information

1
Univ. Bordeaux, Bordeaux F-33076, France; INSERM CIC-P 0005, Bordeaux F-33076, France.
2
CHU de Bordeaux, Bordeaux F-33076, France.
3
Univ. Bordeaux, Bordeaux F-33076, France; INSERM CIC-P 0005, Bordeaux F-33076, France; INSERM U657, Bordeaux F-33076, France.
4
Private Practice Neurologist, Gap F-05000, France.
5
Private Practice Neurologist, Paris F-75000, France.
6
Univ. Bordeaux, Bordeaux F-33076, France; INSERM CIC-P 0005, Bordeaux F-33076, France. Electronic address: philip.robinson@pharmaco.u-bordeaux2.fr.
7
Univ. Bordeaux, Bordeaux F-33076, France; INSERM CIC-P 0005, Bordeaux F-33076, France; CHU de Bordeaux, Bordeaux F-33076, France; INSERM U657, Bordeaux F-33076, France.
8
Univ. Bordeaux, Bordeaux F-33076, France; INSERM CIC-P 0005, Bordeaux F-33076, France; CHU de Bordeaux, Bordeaux F-33076, France; INSERM U657, Bordeaux F-33076, France. Electronic address: annie.fourrier@pharmaco.u-bordeaux2.fr.

Abstract

BACKGROUND:

Since indication extension to children data regarding the effectiveness of levetiracetam in paediatric patients remains limited.

AIMS:

Investigate the real-life effectiveness of levetiracetam in paediatric patients.

METHODS:

Epileptic children (<16 years) who had initiated levetiracetam between 1 October 2006 and 31 March 2007 were included and followed for 1 year by hospital or non-hospital neurologists practising in France.

RESULTS:

Among the 156 identified children, 147 were analysed: 51.7% were female, and mean (SD) age was 9.2 years (4.2). Most patients had either partial symptomatic (30.6%) or partial cryptogenic (26.5%) epilepsy, 92.5% experienced seizures during the 6 months preceding levetiracetam initiation, and 19.2% were on levetiracetam alone at initiation. One-year levetiracetam continuation rate was estimated to be 72.0% (95%CI [63.8; 78.6]). Of the 104 children continuing levetiracetam treatment at end of study, 31.7% were seizure-free during the last six months of follow-up, and 23.1% on levetiracetam alone. Discontinuation of levetiracetam (n = 41) was mainly for insufficient efficacy (58.5% of those concerned).

CONCLUSIONS:

In real-life clinical practice important treatment retention and non-negligible reduction of seizure frequency may be expected.

KEYWORDS:

Antiepileptic drugs; Cohort studies; Effectiveness; Epilepsy; Levetiracetam; Pediatrics

PMID:
24035600
DOI:
10.1016/j.ejpn.2013.07.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center